Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in Zimbabwe.
Adult
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Cohort Studies
Female
HIV Infections
/ drug therapy
Humans
Lost to Follow-Up
Male
Medication Adherence
/ statistics & numerical data
Pregnancy
Proportional Hazards Models
Retrospective Studies
Risk Factors
Sex Factors
Survival Analysis
Zimbabwe
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
07
2020
accepted:
03
10
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Since the scale-up of the HIV "Treat All" recommendation, evidence on its real-world effect on predictors of attrition (either death or lost to follow-up) is lacking. We conducted a retrospective study using Zimbabwe ART program data to assess the association between "Treat All" and, patient-mix, programmatic characteristics, retention and predictors of attrition. We used patient-level data from the electronic patient monitoring system (ePMS) from the nine districts, which piloted the "Treat All" recommendation. We compared patient-mix, programme characteristics, retention and predictors of attrition (lost to follow-up, death or stopping ART) in two cohorts; before (April/May 2016) and after (January/February 2017) "Treat All". Retention was estimated using survival analysis. Predictors of attrition were determined using a multivariable Cox regression model. Interactions were used to assess the change in predictors of attrition before and after "Treat All". We analysed 3787 patients, 1738 (45.9%) and 2049 (54.1%) started ART before and after "Treat All", respectively. The proportion of men was higher after "Treat All" (39.4.% vs 36.2%, p = 0.044). Same-day ART initiation was more frequent after "Treat All" (43.2% vs 16.4%; p<0.001) than before. Retention on ART was higher before "Treat All" (p<0.001). Among non-pregnant women and men, the adjusted hazard ratio (aHR) of attrition after compared to before "Treat All" was 1.73 (95%CI: 1.30-2.31). The observed hazard of attrition for women being pregnant at ART initiation decreased by 17% (aHR: 1.73*0.48 = 0.83) after "Treat All". Being male (vs female; aHR: 1.45; 95%CI: 1.12-1.87) and WHO Stage IV (vs WHO Stage I-III; aHR: 2.89; 95%CI: 1.16-7.11) predicted attrition both before and after "Treat All" implementation. Attrition was higher after "Treat All"; being male, WHO Stage 4, and pregnancy predicted attrition in both before and after Treat All. However, pregnancy became a less strong risk factor for attrition after "Treat All" implementation.
Sections du résumé
BACKGROUND
Since the scale-up of the HIV "Treat All" recommendation, evidence on its real-world effect on predictors of attrition (either death or lost to follow-up) is lacking. We conducted a retrospective study using Zimbabwe ART program data to assess the association between "Treat All" and, patient-mix, programmatic characteristics, retention and predictors of attrition.
METHODS
We used patient-level data from the electronic patient monitoring system (ePMS) from the nine districts, which piloted the "Treat All" recommendation. We compared patient-mix, programme characteristics, retention and predictors of attrition (lost to follow-up, death or stopping ART) in two cohorts; before (April/May 2016) and after (January/February 2017) "Treat All". Retention was estimated using survival analysis. Predictors of attrition were determined using a multivariable Cox regression model. Interactions were used to assess the change in predictors of attrition before and after "Treat All".
RESULTS
We analysed 3787 patients, 1738 (45.9%) and 2049 (54.1%) started ART before and after "Treat All", respectively. The proportion of men was higher after "Treat All" (39.4.% vs 36.2%, p = 0.044). Same-day ART initiation was more frequent after "Treat All" (43.2% vs 16.4%; p<0.001) than before. Retention on ART was higher before "Treat All" (p<0.001). Among non-pregnant women and men, the adjusted hazard ratio (aHR) of attrition after compared to before "Treat All" was 1.73 (95%CI: 1.30-2.31). The observed hazard of attrition for women being pregnant at ART initiation decreased by 17% (aHR: 1.73*0.48 = 0.83) after "Treat All". Being male (vs female; aHR: 1.45; 95%CI: 1.12-1.87) and WHO Stage IV (vs WHO Stage I-III; aHR: 2.89; 95%CI: 1.16-7.11) predicted attrition both before and after "Treat All" implementation.
CONCLUSION
Attrition was higher after "Treat All"; being male, WHO Stage 4, and pregnancy predicted attrition in both before and after Treat All. However, pregnancy became a less strong risk factor for attrition after "Treat All" implementation.
Identifiants
pubmed: 33075094
doi: 10.1371/journal.pone.0240865
pii: PONE-D-20-20707
pmc: PMC7571688
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0240865Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
Ther Clin Risk Manag. 2020 Mar 04;16:169-180
pubmed: 32184609
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29314658
PLoS One. 2019 Jan 23;14(1):e0210126
pubmed: 30673744
J Int AIDS Soc. 2019 Oct;22(10):e25401
pubmed: 31647613
PLoS One. 2018 Nov 26;13(11):e0207656
pubmed: 30475865
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):387-99
pubmed: 26959190
J Int AIDS Soc. 2020 Mar;23(3):e25458
pubmed: 32128964
J Int AIDS Soc. 2019 Apr;22(4):e25279
pubmed: 30993854
Med Teach. 2013 Jun;35(6):e1181-96
pubmed: 23705658
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25321
pubmed: 31321918
PLoS One. 2019 Jul 10;14(7):e0218555
pubmed: 31291273
PLoS One. 2014 Sep 29;9(9):e105645
pubmed: 25265158
MMWR Morb Mortal Wkly Rep. 2017 Aug 04;66(30):813-814
pubmed: 28771456
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438
pubmed: 29287029
Trop Med Int Health. 2018 Feb;23(2):136-148
pubmed: 29164754
PLoS One. 2020 Jan 7;15(1):e0222309
pubmed: 31910445
BMC Res Notes. 2018 Feb 17;11(1):134
pubmed: 29452597
PLoS Med. 2017 Jul 25;14(7):e1002360
pubmed: 28742829
J Infect Dis. 2020 Aug 4;222(5):755-764
pubmed: 31682261
AIDS Care. 2016;28 Suppl 3:67-73
pubmed: 27421053
PLoS One. 2010 May 11;5(5):e10584
pubmed: 20485670
J Int AIDS Soc. 2020 Feb;23(2):e25455
pubmed: 32091179
Reprod Health. 2017 Oct 5;14(1):124
pubmed: 28982365
PLoS Med. 2019 Jun 10;16(6):e1002822
pubmed: 31181056
PLoS One. 2020 Jan 14;15(1):e0227572
pubmed: 31935240
BMC Pregnancy Childbirth. 2018 Dec 29;18(1):510
pubmed: 30594161
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
J Int AIDS Soc. 2020 Apr;23(4):e25479
pubmed: 32319203
PLoS Med. 2019 Sep 16;16(9):e1002912
pubmed: 31525187
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Trop Med Int Health. 2015 Aug;20(8):1015-32
pubmed: 25877007
J Int AIDS Soc. 2019 Jul;22(7):e25331
pubmed: 31623428
AIDS Res Ther. 2020 May 18;17(1):19
pubmed: 32423457
BMC Public Health. 2019 Jan 28;19(1):117
pubmed: 30691425
J Int AIDS Soc. 2019 Feb;22(2):e25239
pubmed: 30734510